Agrawal, UtkarshBedston, StuartMcCowan, ColinOke, JasonPatterson, LynseyRobertson, ChrisAkbari, AshleyAzcoaga-Lorenzo, AmayaBradley, Declan TFagbamigbe, Adeniyi FrancisGrange, ZoeHall, Elliott C RJoy, MarkKatikireddi, Srinivasa VittalKerr, StevenRitchie, LewisMurphy, SiobhánOwen, Rhiannon KRudan, IgorShah, Syed AhmarSimpson, Colin RTorabi, FatemehTsang, Ruby S Mde Lusignan, SimonLyons, Ronan AO'Reilly, DermotSheikh, Aziz2022-10-142022-10-142022-10-15Agrawal, U, Bedston, S, McCowan, C, Oke, J, Patterson, L, Robertson, C, Akbari, A, Azcoaga-Lorenzo, A, Bradley, D T, Fagbamigbe, A F, Grange, Z, Hall, E C R, Joy, M, Katikireddi, S V, Kerr, S, Ritchie, L, Murphy, S, Owen, R K, Rudan, I, Shah, S A, Simpson, C R, Torabi, F, Tsang, R S M, de Lusignan, S, Lyons, R A, O'Reilly, D & Sheikh, A 2022, 'Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters : pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales', The Lancet, vol. 400, no. 10360, pp. 1305-1320. https://doi.org/10.1016/S0140-6736(22)01656-70140-6736RIS: urn:874F838E134EC9EB6DEA28C54FC93968https://hdl.handle.net/2164/19379This work was funded by the National Core Studies–Immunity group. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20060), with support from the DaC-VaP-2 study also funded by UK Research and Innovation (grant ref MC_PC_20058). The study entitled “Use of national linked health care, serological data, and viral genomic data to identify and characterise post-third and -booster dose vaccine breakthroughs at a population level” is a partnership between the University of Edinburgh, Swansea University, Oxford University, Queen’s University of Belfast, University of St Andrews, and The Office for National Statistics. The authors would like to acknowledge all other project collaborators not involved in these analyses but who are contributing to wider discussions and preceding outputs. EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE–The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and is delivered through Health Data Research UK. Additional support has been provided through Public Health Scotland and Scottish Government Director-General Health and Social Care.161071542engSDG 3 - Good Health and Well-beingR MedicineMedical Research Council (MRC)MR/R008345/1UK Research and Innovation (UKRI)MC_PC_20060MC_PC_20058MC_PC_19004Supplementary DataRJournal article10.1016/S0140-6736(22)01656-7https://www.sciencedirect.com/science/article/pii/S014067362201656740010360